Adenosine Therapeutics, LLC

Company
Adenosine Therapeutics is a world leader in the development of novel pharmaceutical products that target adenosine receptor subtypes. The companyís most advanced product is Apadenoson, a highly selective A2A agonist, which is in Phase III clinical development for use as a stress agent during cardiac imaging. The Company is also developing drugs for the treatment of asthma, diabetes, Parkinsonís disease, cancer, ophthalmic disease and inflammatory indications such as sepsis, heart attack, ischemia-reperfusion injury, sickle cell crisis, vascular injury, arthritis, spinal cord injury, COPD, and inflammatory bowel disease.

Current Investors/Backers
Adenosine Therapeutics, Inc. is backed by a group of top tier investors including Novartis Option Fund.